Onco Actu du 26 octobre 2016

	1. Biologie
Solving the Lack of Diversity in Genomic Research [MIT Technology Review] An overwhelming majority of the data collected is from people of European ancestry. But researchers are trying to change that.
	2.10 Etiologie - Alcool
Women now drinking 'almost as much alcohol as men' [NHS Choices] Overall, this is a good data set and likely to be the best we can get on this question, but the data still really needs to be considered to be estimates and not definite figures.
	2.6 Etiologie - Environnement
Exclusive: WHO cancer agency asked experts to withhold weedkiller documents [Reuters] Asked about its actions, the agency told Reuters on Tuesday it was seeking to protect its work from external interference and defending its panels' freedom to debate evidence openly and critically.
	3.1 Tabac
ASCO Concerned by Continued Toll Taken by Cigarette Use Taking in the U.S., Particularly Among Southern States [ASCO] We are chiefly concerned with the study’s findings there are still 40 million current adult cigarette smokers in the U.S. and that up to 40% of cancer deaths in men are caused by smoking in the southern states. Tobacco use is the leading preventable cause of cancer with 480,000 American lives claimed each year by smoking-related illnesses.
	3.1.1 Tabac - e-cigs
E-cigarettes could be used to help combat obesity in smokers trying to quit: study [Reuters] In a review published in the journal Nicotine & Tobacco Research, the scientists found that it's the nicotine in cigarettes that makes smokers less likely to overeat, and suggested e-cigarettes, which contain nicotine but no tobacco, may help prevent them from eating too much when they quit.
	4.5 Dép., diag. & prono. - Colorectal
There’s an Easier Way to Screen for Colon Cancer [Time] Colonoscopy may be getting all the attention as the preferred way to screen for colon cancer, but a tried-and-true method that doesn’t require a hospital visit (or as much discomfort) may be just as effective.
	5. Traitements
New UK research illuminates new developments for anticancer treatment [Pharmafile] By injecting polymer beads into arteries to ‘feed’ tumours, scientists are able to starve them of oxygen and nutrients by blocking blood flow. The polymers then release an anticancer drug directly into the tumour, reducing systemic side-effects.
Researchers deploy viruses to improve cancer treatments [Cancer Research UK] Professor Alan Melcher and his colleagues are developing viruses that could be injected into the bloodstream of skin cancer patients and are designed to start attacking the tumour. This attack would flag the disease to immune system which, if activated by an immunotherapy drug, could prove an even more effective approach to treating the disease.
	5.10 Traitements - Essais
OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer [OncoGenex] Borealis-2 is an investigator-sponsored, randomized Phase 2 trial evaluating a survival benefit with apatorsen in combination with docetaxel treatment compared to docetaxel treatment alone in approximately 200 patients with metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy.
	5.12 Immunothérapies
New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients [BMS] First presentation of Phase 2 CheckMate -205 cohort C data in classical Hodgkin lymphoma patients following treatment with autologous hematopoietic stem cell transplantation and brentuximab vedotin.
Tetra-punch against solid tumors [NIHilist's Immunology Blog] Of course, it is difficult to compare outcome in mouse study versus human study. In humans, even single approach with anti-PD1 antibody frequently leads to lung or liver toxicity. Now imagine injecting cancer patients with 4 different immunotherapeutics.
	5.2 Pharma
AZ’ Lynparza delays ovarian cancer progression, data show [PharmaTimes] Full results of SOLO-2 are to be presented at a forthcoming medical meeting.
Readying for pricing fight, drug lobby to add $100 million to coffers [STAT] The Pharmaceutical Research and Manufacturers of America is raising its annual membership dues by 50 percent, according to a Politico report on Tuesday morning, which will increase its yearly take to $300 million total.
Drug lobby adds $100M to war chest ahead of pricing battle [Politico] The pharmaceutical lobby is requiring member companies to fork over an additional $100 million per year as the industry gears up for a bruising post-election battle over drug prices.
	5.2.3 Pharma - économie
Merck Revenue and Profit Rise on Cancer Drugs, Vaccines [Wall Street Journal] For the third quarter, Keytruda posted sales of $356 million, up from $159 million in the same quarter last year. J.P. Morgan analysts expect the latest regulatory approval in lung cancer to help more than double annual sales of the drug to $3.5 billion in 2017 from an expected $1.3 billion this year.
	5.3 Traitements - FDA, EMA, NICE...
The FDA’s Controversial Duchenne Drug Approval And The Moral Impulse To Rescue [Health Affairs Blog] How can a regulator approve a drug, while simultaneously questioning the quality of the evidence about its efficacy? Has the FDA succumbed to the pleas of desperate parents and in so doing, lowered its scientific standards? Or has it demonstrated compassion and a path forward that is justifiable?
	6.1 Observation
Let's be honest: the NHS is costing thousands of lives [The Telegraph] Each year, 2,500 people die of breast cancer who would not have died if they lived in Belgium. Each year, 3,200 die from bowel cancer who would not have died if they lived in the Netherlands.
	6.10.1 Politiques (USA)
ASCO Recommends Key Priorities for 21st Century Cures [ASCO] The 21st Century Cures Act is designed to accelerate the discovery, development, and delivery of promising new treatments to patients. In the weeks ahead, it’s expected that Congress will amend and streamline the legislation in order to secure the votes needed to pass both the House and Senate. ASCO has weighed in heavily throughout the development of the legislation and has continued to advocate for passage of the bill.
	6.5 Médecines alternatives
Regrets of a Naturopath [In the Pipeline] One of the things that seems to have caused Britt Hermes to throw her hands up and leave (rightly so) was that her former boss was importing and prescribing an unapproved drug for cancer patients. This stuff, known as Ukrain, has apparently been kicking around the cancer-cure underground for a while.